Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Epigenetic Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KDM4A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | KDM4A Recombinant Protein (Active Catalytic Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for enzymatic assays. |
View KDM4A Products |
| Negative Control | KDM4A (H188A/D191A) Catalytically Inactive Mutant High purity (>95%), Sequence Verified. Essential for specificity validation. |
View KDM4A Products |
| Gene Delivery | KDM4A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target engagement assays. |
View KDM4A Products |
| Validator | KDM4A siRNA Set For target knockdown and phenotypic verification. |
View KDM4A Products |
| Related Target A | KDM4B Subfamily homolog; critical for off-target selectivity screening. |
View KDM4B Products |
| Related Target B | KDM4C Subfamily homolog; highly conserved catalytic pocket, essential for selectivity panels. |
View KDM4C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily selectivity screening (KDM4A vs KDM4B/C) | Highly purified recombinant catalytic domains for KDM4 subfamily members verified by Mass Spectrometry. |
| Assay signal interference from protein impurities | High-purity (>95% by SDS-PAGE) and endotoxin-controlled preparations to ensure low background. |
| Lack of rigorous negative controls for enzyme activity | Catalytically inactive mutant proteins (H188A/D191A) available as negative control standards. |
| False positives in high-throughput screening | Sequence-verified target-specific siRNA sets included for orthogonal validation of target knockdown. |
Live KDM4A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KDM4A therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum histone demethylase inhibitors to highly selective small molecules and targeted protein degradation (PROTACs). KDM4A (also known as JMJD2A) is frequently overexpressed in various cancers, including prostate, breast, and colorectal malignancies, where it drives oncogene expression and genomic instability. As first-generation pan-KDM inhibitors reach the clinic, the next wave of R&D is targeting isoform-selective pocket binding and PROTAC-mediated degradation to overcome the high homology within the KDM4 subfamily.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic institutions, Biotech startups | Prostate Cancer, Breast Cancer | Selectivity Assay (Need KDM4A vs KDM4B/C/D Mutant and WT Proteins) |
| PROTACs / Degraders | Epigenetic-focused Biopharma | Solid Tumors, Drug-resistant Cancers | Target Engagement & Ternary Complex Validation (Need High-Purity Recombinant Proteins & Lentivirus) |
| Combination Therapies | Clinical-stage Oncology Companies | EGFR-TKI Resistant NSCLC | Synergy Validation (Need siRNA knockdown combined with small molecule controls) |